Advocacy Update
CanPKU+ Submits Feedback on Draft Recommendation for Loargys
July 2026
Canadian PKU and Allied Disorders Inc. (CanPKU+) has submitted feedback to Canada's Drug Agency (CDA-AMC) on the draft recommendation for Loargys (pegzilarginase), a therapy under review for arginase 1 deficiency (ARG1-D), also known as hyperargininemia.
Summary
CanPKU+ supports CDA-AMC's draft recommendation to reimburse Loargys with conditions. We appreciate the Committee's recognition of the significant unmet need in ARG1-D, the serious and progressive nature of the condition, and the challenges of generating evidence in ultra-rare diseases.
Our feedback focused on making sure the final recommendation supports meaningful, equitable, and continuous access for eligible patients who are clinically benefiting from treatment.
Why This Matters
ARG1-D is a rare inherited metabolic disorder that can lead to progressive neurological, neuromotor, and cognitive decline. For patients and families, access to treatment is not only about laboratory values. It is also about preserving mobility, communication, learning, daily function, participation in school and community life, and quality of life.
Current supportive management can be demanding for families and may not address the underlying disease mechanism. For a progressive rare disease, preventing further deterioration and maintaining function can be deeply meaningful outcomes.
What CanPKU+ Asked CDA-AMC to Clarify
While CanPKU+ agrees with the positive draft recommendation, we asked CDA-AMC to refine the reimbursement and renewal conditions so they do not unintentionally create barriers to continued access.
1. Recognize clinical benefit, not only a single lab threshold
Plasma arginine levels are an important treatment marker, but response may not always be fully captured by one laboratory threshold. CanPKU+ asked that renewal criteria allow treating physicians to document clinical response using both biochemical and clinical indicators.
2. Include stabilization as a meaningful outcome
In a progressive condition, maintaining function, preventing further neurological decline, reducing metabolic crises, improving or maintaining quality of life, or showing other patient-specific benefits may all be meaningful signs of response.
3. Avoid penalizing temporary arginine fluctuations
Temporary or explainable arginine increases can occur during illness, infection, physiological stress, catabolism, puberty, pregnancy, or postpartum status. We asked that these fluctuations not be treated as automatic treatment failure when the specialist determines the patient's overall trajectory remains stable or improved.
4. Protect continuity of access
CanPKU+ emphasized that treatment interruptions may have serious consequences for patients and families. We asked that continuity be protected during implementation, price negotiation, transition from trial or special access pathways, and renewal review.
5. Consider real-world access barriers
Families living outside major metabolic centres may face travel, time, financial, and caregiving barriers. We asked that implementation planning consider blood collection procedures, trained metabolic teams, home administration training, home nursing or local supports where needed, and clear troubleshooting pathways.
What Happens Next
CDA-AMC will review stakeholder feedback before issuing a final recommendation. Reimbursement decisions and implementation timelines may then vary across participating public drug plans.
CanPKU+ will continue to advocate for reimbursement criteria that reflect the lived realities of ARG1-D and other inherited metabolic disorders, including the importance of stabilization, prevention of deterioration, equitable access, and continuity of care.
View CanPKU+ Feedback Submission
This article is for community information and advocacy awareness only. Treatment decisions should be discussed with a qualified metabolic specialist or health care provider.
Back to top
